Media OutReach
Bora Delivers Highest Operating Cash Flow Margin Since 2020, Enabling 2026 Bolt-On Investments from a Larger, Stronger Platform
Board Proposed NT$10 Cash Dividend Per Share
HONG KONG SAR – Media OutReach Newswire – 11 March 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for full year 2025 and provides 2026 outlook.
FY25 Business and Financial Highlights
- Company reported full year revenues, with discontinued operations reported separately, of NT$19,014 million, up 9.11% from the prior year and basic EPS of NT$23.90, or NT$2.63 for the fourth quarter. Full year EPS represents a 24.22% year-over-year decline, mostly due to a net loss per share of NT$11.24 from discontinued operations.
- In the fourth quarter, following the completion of tech transfer of production transitions out of the Plymouth area in Minnesota, the COGS of those originally Plymouth-made inventories have been reconsolidated to COGS line. Hence on a like-for-like basis when compared with other quarters in 2025, fourth quarter gross margin would have been approximately 38-39%. The reported high single-digit percentage sequential decline in gross margin, which also led to softened operational leverage, was primarily attributable to a temporary slowdown in DLS orders from following the entry of a new competitor in Nov. with limited launch visibility during the quarter. Higher effective tax rates during the quarter were a direct result of less sell-through downstream from related party transactions of the internally manufactured generic products. In addition, heightened generics competition of Topiramate ER, a leading generics product of Upsher-Smith, was also a negative gross margin mover.
- Management believes the 4Q25 OPEX profile more accurately reflects the expanded operating platform and our strategic repositioning into new focus areas. Sales and marketing expenses increased seasonally in line with market share cadence and channel expansion initiatives, while R&D spending sat on the disciplined side. Gross margin expansion serves as the key lever for operating leverage as scale improves fixed-cost absorption.
- Pharma sales revenue remained volatile in the fourth quarter as legacy inventory phased out and new product approvals remain pending. Generics portfolio competitiveness remains a key focus area in the near term for both top line and gross margin. Nevertheless, led by vigabatrin franchise, Bora’s rare disease portfolio continued to gain impressive market share across dosage forms. The Company aims to actively refill pipelines in 2026 to regain profitable growth.
- The Group’s CDMO business delivered another strong quarter in both revenues and gross margin. Supported by expanded capacity and the addition of new dosage forms, CDMO revenues grew 53.8% year-over-year in 2025 to NT$10.64 billion, including internal orders. Excluding internal orders, revenues reached NT$7.50 billion, representing a 19.53% increase compared to 2024.
- As 2025 marked a year of post-merger integration and strategic consolidation, Bora achieved its highest operating cash flow margin in recent years at 34.74% in the fourth quarter, compared with -4.00% in the same period last year. This improvement reflects the transformation of the Bora Group into a more efficient organization operating on a larger and stronger platform. The Board has proposed a NT$10 cash dividend per share, demonstrating confidence in the Group’s strengthened cash generation and commitment to delivering sustainable returns to shareholders, reaching the highest yield rate proposed.
- Share capital increased 3.18% during the quarter from employee stock option exercise and convertible bond conversions.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “2025 represented a pivotal year for Bora Group. Beyond post-acquisition integration, it was a year of disciplined capital allocation and balance sheet stewardship. Having stepped onto a larger growth platform, we deliberately reassessed optimal cash deployment, portfolio mix of both CDMO and Pharma Sales businesses and forthcoming return metrics under a stable equity structure. One year after closing the 2024 acquisitions, we achieved our highest operating cash flow margin, marking a complete turnaround from the same period last year when the Group first transitioned to its current scale.
The external environment was marked by significant shifts. We operated against a backdrop of renewed U.S. trade and industrial policy shifts, triggering supply chain realignment and foreign exchange fluctuations. At the same time, rapid AI adoption began reshaping manufacturing competitive dynamics, if not capital market funding flow. Concurrently, the Group faced competition in a handful core generic products that remain meaningful contributors to revenue and EBITDA. Discontinued operations aside, based on the reclassified financial statements for 2025 and 2024, EBITDA for continued operations declined 19.0% compared to 2024, but remains 12.5% higher than 2023, underscoring the structurally higher revenues and earnings base established over the past 2 years.
Despite these headwinds, the Group remained profitable and has preserved financial flexibility. Notably, we funded Bora’s largest CDMO CAPEX program in our history and executed the business transformation of Upsher-Smith entirely within existing credit facilities, without incremental equity dilution. While value expansion of this new Bora Group platform took longer than the Company expected, we believe the year demonstrates the resilience of our operating model, disciplined financial management, and our ability to execute strategic investments while maintaining earnings and balance sheet integrity.
We are especially delighted to share the contract renewal with GSK earlier this year. From day one, this partnership was built on mutual trust and a shared commitment to quality. With the latest developments, we are looking at a decade of collaboration with GSK and committing through 2030 speaks to our shared focus on value and reliability. We have also established new partnerships with several high-growth pharmaceuticals over the past few months, further expanding our client base across our North American network. These partners share our belief in an integrated and orchestrated supply chain model, leveraging our multi-site platform to support development, manufacturing, and commercialization needs.
To sum up, the CDMO rolling 12-month external order backlog, after a good quarter of digestion and less working days, arrived at US$264 million. Total external wins in 2025 reached a phenomenal US$482 million, of which 89% were commercial-stage orders and 16 molecules in pre-commercial stage, providing solid visibility into 2026 and beyond especially for Canada and Baltimore sites. At the same time, Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio.
On the pharma sales side, Upsher-Smith today represents a structurally repositioned platform. Performance has been increasingly driven by lifecycle management, including continued maximization of the infantile spasm franchise, alongside active pipeline replenishment with a heightened focus on differentiated assets, particularly NCEs in rare diseases. Within Generics, we have confirmed 7 launches in 2026, including the recently approved Cyclosporine and an in-licensed product indicated for hyponatremia. We are also observing a more constructive environment for DLS than initially anticipated, with 2026 year-to-date market share maintained. Last but not least, based on our current knowledge of the relevant U.S. patent rulings, if TWi receives approval for Cladribine (gMavenclad), Upsher-Smith, as the exclusive distributor, would be positioned to launch the product in the U.S., subject to customary regulatory and commercial considerations.
Beyond our base expectation of launching more than 10 generic products annually, we have identified revenue and EBITDA accretive, bolt-on investment opportunities to further strengthen this business in 2026. These include progressively expanding our injectable and 505(b)(2) portfolios to enhance differentiation and economics, as well as deepening penetration across proprietary and specialty distribution channels. When we exit this year with a more diversified and better-calibrated product mix, we expect improved earnings resilience and more stable growth trajectory going forward.”
FY25 Operational Achievements & 2026 Outlook
Global CDMO Operations
Global CDMO operations revenue reached record highs for both the quarter and the full year, accounting for approximately 45.78% of reported revenues in the quarter and 39.43% for FY2025. In total, 2.5 billion doses were developed and manufactured. Revenue contribution from the top 20 global pharmaceutical companies declined slightly to 29% from the low-30% range previously, primarily reflecting the addition of several fast-growing pharmaceutical clients to the Company’s portfolio in recent years, with increasing contributions from their successful product launches.
As the Company continues to expand its CDMO capacity and capabilities, including approximately 10% additional aseptic fill/finish capacity and a net ~3% expansion in solid and liquid dosage capacity, Bora Group monitors utilization rate carefully across facilities. While the Company remains confident that investing in U.S. manufacturing capacity is strategically sound, given the importance of the U.S. pharmaceutical market and supply chain resilience, capital allocation must also align with prevailing industry investment cycles. Against this backdrop, a structural supply gap in single-use drug substance (DS) bioreactor capacity, projected to grow at an estimated 8–10% CAGR, reinforces the rationale for continued investment in Tanvex Biopharma (branded as Bora Biologics) as Bora Group expands its CDMO platform. Supported by a more favorable funding environment for early-stage biotech companies in the US, rapidly growing biologics pipeline, increasing FDA approvals, long product lifecycles, and Tanvex’s integrated access to Bora’ Group’s drug product (DP) fill/finish capabilities, the strategic platform presents a compelling long-term value creation opportunity. While this represents a near-term drag on reported earnings, the Company believes these investments are necessary to position Bora Group for long-term participation in the CDMO market that values quality and OTIF (On Time, In Full) delivery.
Pharma Sales Operations
Pharma Sales operations generated revenue of NT$2.64 billion in the fourth quarter, marking one of slowest quarters since the Upsher-Smith merger. For the full year, Pharma Sales declined 11.30% compared to 2024, excluding the impact of discontinued operations related to delisted products, and accounted for 60.48% of total revenues.
A key leading indicator in specialty pharma is the number of new patients, and across the Vigabatrin franchise, Upsher-Smith continues to demonstrate positive momentum on this front. Upsher-Smith intends to pursue enhanced customer segmentation to further increase salesforce effectiveness in 2026 with investments in key commercial functions and patient access to increase salesforce effectiveness.
Recent Investor Conference
Bora will host an English online earnings call at 9:30 p.m. Taiwan time on Mar. 12th, 2026, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:00 p.m. on Mar. 19th, 2026. Both events will cover the Company’s 2025 financial and business results and 2026 outlook.
English Online Earnings Presentation Link: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5255333/bora-pharmaceuticals-otcqx-boray-twse-6472
Bora will participate in 2026 Jefferies Asia Forum in March in Hong Kong and an East coast NDR in NYC and Boston. For 1:1 meetings with management, please contact your Jefferies and Sinopac representative.
Bora 2026 Earnings Schedule
Q1 2026: Expected in the 2nd week of May 2026
Q2 2026: Expected in the 2nd week of Aug 2026
Q3 2026: Expected in the 2nd week of Nov 2026
Q4 2026: Expected in the 2nd week of Mar 2027
Hashtag: #Bora
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Media OutReach
No Judgement, No Awkwardness: More Hongkongers Are Opening Up to AI for Mental Health Support
A newly completed Hong Kong study suggests there may finally be a way to bridge that gap. The AIM Greater China Psychology Research Group has completed a Hong Kong-based study conducted in the 2025–2026 academic year, comparing the effectiveness of human hypnotherapists against AI in delivering hypnotic experience-based stress relief experiences. The findings were striking: a significant proportion of participants felt that both approaches yielded virtually equivalent levels of relaxation — and more than 60% reported preferring their AI session after the fact.
Over 400 Applicants: A Reflection of a Generation in Need of Being Heard
The research team recruited participants experiencing family-related stress via Facebook. Within a short period of the post going live, over 400 individuals voluntarily applied — a figure that speaks not only to the pervasiveness of stress in modern life, but also to a growing willingness among the public to prioritise their own emotional wellbeing and actively seek self-care solutions.
From the applicant pool, 48 participants were randomly selected to take part. Each participant underwent two separate hypnotic experience stress relief audio sessions, each lasting approximately one hour — one recorded by a human hypnotherapist, and one fully generated by AI, including both the script and voice. Participants then compared their personal experiences of both sessions.
What Humans Can Do, AI Can Do Too
In the most critical area of comparison — stress relief effectiveness — the largest single group of participants (41.7%) rated the AI and human sessions as equally effective. On a scoring basis, the AI hypnotic experience averaged approximately 2.92 points, compared to 2.58 points for the human session — with AI coming out marginally ahead.
The study further found that nearly 90% of participants indicated they would enjoy a session if it genuinely helped them feel relaxed. In other words, what people truly care about is whether it works — not whether the voice behind it belongs to a human or a machine. On this front, AI has passed the test.
Over 60% More Willing to Share Their Feelings with AI
The results around personal preference were perhaps the most eye-opening. When asked which session they enjoyed more, 62.5% of participants chose the AI experience — and among women, that number climbed even higher, to 68.4%.
So what made AI the preferred choice? Researchers believe it comes down to one simple thing: feeling safe. With AI, there is no worry about being judged. No fear of saying the wrong thing. No awkwardness. About 1 in 4 participants said they actually found it easier to talk openly with AI — because it communicates in a way that feels clear, calm, and natural, much like everyday conversation.
The truth is, some things are just easier to say when no one is watching. That is not a flaw in human nature — it is simply how many of us work.
When it came to privacy, the findings were equally reassuring. More than half of all participants said they had no concerns about AI handling their personal information. Only a very small number — just 2.08% — said they felt uncomfortable. This points to a growing sense of trust in AI tools among the general public.
AI Reads the Data; Therapists Read the Person
Beyond the hypnotic experience itself, the local research team also evaluated AI’s capability as an analytical tool — with equally impressive results.
AI was able to rapidly process large volumes of participant responses, objectively assess individual stress levels, and identify underlying patterns. For instance, AI identified that 35% of participants independently expressed a desire for “personal space” or “better soundproofing” in their homes. On the surface, these may seem like trivial lifestyle concerns — yet AI connected this pattern to the reality of Hong Kong residents living in constrained spaces, highlighting a deeper psychological sense of having “nowhere to breathe”. This level of insight would be difficult to uncover through manual review of dozens of questionnaires alone.
AI also observed that many participants habitually occupied the role of “problem-solver” or “mediator” within their households, suppressing their own emotional needs in the process. Researchers noted that this reflects a widely recognised social phenomenon — the pressures faced by eldest daughters and the so-called “sandwich generation,” caught between the responsibilities of caring for ageing parents and raising children. AI’s ability to rapidly identify these hidden emotional burdens allows therapists to bypass lengthy preliminary assessments and focus more swiftly on the core issues that require their attention.
AI Is Here to Help, Not to Take Over
The local research team emphasises that the study was never intended to position AI as a replacement for human therapists. Rather, the aim is to explore how the two can work in tandem. Much like how blood test reports assist physicians in diagnosis, AI can play an analogous supporting role in the mental health field — organising data, identifying patterns, and lowering barriers to seeking help, so that mental health professionals can direct their energy towards the moments that truly require a human touch.
Those who proactively seek psychological support remain a minority, often deterred by the fear of inconvenience, social stigma, or the awkwardness of speaking up. If AI can serve as the bridge that encourages more people to take that first step, that alone may be its most meaningful contribution to society.
Hashtag: #HypnosisInstitute
The issuer is solely responsible for the content of this announcement.
About Hypnosis Institute
Hypnosis Institute is dedicated to helping people in Hong Kong lead healthier and more fulfilling lives through hypnotic experience. We offer accessible and practical hypnotic experience training programmes designed to integrate hypnotic techniques into everyday life, with a focus on stress management, emotional wellbeing, and personal growth.
Hypnosis Institute is Hong Kong’s only hypnotic experience professional development platform that simultaneously operates a research group, social innovation group, practical training group, crisis psychological support group, charitable initiatives, networking events, therapeutic services, and a comprehensive training pathway.
As the sole Hong Kong chapter of the Association for Integrative Medicine (AIM) in the United States, the sole overseas Hong Kong academy of UK educational institution Study House (Quality Licence Scheme), and the sole specialist hypnotic experience training school in Hong Kong under Cambridge International College in the United Kingdom, Hypnosis Institute provides internationally recognised qualifications that contribute to the advancement of the industry.
Founder Charles Leung is a trainer of trainers in the field of hypnotic experience, and has been specially appointed by the Association for Integrative Medicine as the Chief Instructor for Specialist hypnotic experience in Greater China. He has trained over 1,000 hypnotherapists and instructors, upholding the highest standards of professional development in the mental health field.
The Institute’s programmes integrate a comprehensive range of methodologies, including hypnotic experience combined with MBTI personality profiling, DISC behavioural analysis, mental health coaching, emotional education, and the HiddenMe Cards inner child tool — providing a holistic and personalised approach to hypnotic experience practice. Instructors specialise in paediatric hypnotic experience, Internal Family Systems (including inner child) hypnotic experience, stress and insomnia relief hypnotic experience, interpersonal relationship hypnotic experience, as well as hypnotic experience in reminiscence and palliative care.
Driven by the belief that everyone can harness the power of hypnotic experience to enhance their mental wellbeing, Hypnosis Institute is committed to sharing psychological knowledge and providing professional support in the areas of emotional management, life challenges, and the professional development of the hypnotic experience industry.
Follow us at hypnosisinstitute.com.hk, 
Facebook, 
Instagram and 
YouTube for the latest updates.
Held at deMori @ FCC Signature, the event featured a live platform demonstration, partner showcase, and networking sessions aimed at facilitating engagement between founders, advisors, and investors.
Introducing CapitalOS
CapitalOS, BizPal’s corporate finance platform, was presented through a live demonstration during the event. The system integrates operational, brand, and financial data into a structured framework designed to support investor readiness and due diligence.
According to BizPal, the platform is intended to help SMEs organise their business information into formats aligned with investor expectations, enabling clearer communication during fundraising discussions.
“SMEs should never walk into a funding conversation unsure of their numbers,” said Ms. Anya Tan, CEO of BizPal Malaysia.
MOUs Expand Distribution Network
The event also included the signing of Memoranda of Understanding between BizPal and two Malaysian partners, My Education Platform and VA Partners. Both organisations will serve as authorised distributors of BizPal’s education and advisory programmes across Malaysia.
The partnerships expand BizPal’s reach within the SME ecosystem by working with local organisations that support business development and capability building.
“Partnering with BizPal allows us to introduce structured, investor-ready methodologies to the SME community we serve,” said Mr. Jeff Lee, Director, My Education Platform.
A representative from VA Partners is expected to provide a statement following final endorsement.
Global Mentorship Exchange (GMX)
During the event, BizPal also presented the Global Mentorship Exchange (GMX), an ecosystem initiative designed to connect experienced business leaders with high-potential entrepreneurs.
The initiative provides a structured environment for mentorship supported by data-based evaluation and standardised assessment criteria aligned with investor expectations. GMX was first introduced during BizPal’s Data Fundraising Masterclass in December 2025 and was presented to a broader network of partners and investors at BizPal Day.
Next Steps
Following the event, BizPal plans to expand the adoption of CapitalOS and continue developing its partner network across Malaysia and the ASEAN region.
Hashtag: #NoDataNoTalk #DataFundraising #InvestorReady #CapitalReadiness #FinTech #BusinessValuation #ASEANSMEs #BizPalDay
https://www.bizpal.tech/
https://www.facebook.com/simplyfi.sg
The issuer is solely responsible for the content of this announcement.
About BizPal
BizPal provides data-driven corporate finance solutions designed to help ASEAN SMEs become investor-ready. Its platform, CapitalOS, integrates operational, strategic, and financial data into a unified system that supports business evaluation and investor engagement.
Media OutReach
Vinhomes Green Paradise Can Gio And IHG Hotels & Resorts Partner To Bring Four International Hotel Brands To The Coastal Mega Urban Development
Under the agreement, IHG will develop four hotels with a total of more than 1,000 rooms at Vinhomes Green Paradise Can Gio, including InterContinental Saigon Can Gio with 400 rooms, Crowne Plaza Saigon Can Gio with 400 rooms, Holiday Inn Express Saigon Can Gio with 130 rooms, and Garner Saigon Can Gio with 130 rooms.
InterContinental Saigon Can Gio, a world-renowned luxury brand, will deliver premium hospitality experiences tailored to international travelers and domestic guests seeking high-end accommodation. Crowne Plaza Saigon Can Gio, one of the largest upscale hotel brands globally, will cater to frequent travelers with modern, flexible spaces designed to optimize productivity and foster connections.
Holiday Inn Express Saigon Can Gio and Garner Saigon Can Gio will expand the destination’s accommodation offering with efficient, high-quality stays focused on value, making the development more accessible to a broader range of guests. This also marks the official debut of both brands in the Vietnamese market.
According to the development timeline, Holiday Inn Express Saigon Can Gio and Garner Saigon Can Gio are expected to open in 2028, followed by InterContinental Saigon Can Gio and Crowne Plaza Saigon Can Gio in 2030.
In this partnership, Vinpearl, a member of Vingroup, will act as the project operator and lead the collaboration with IHG Hotels & Resorts, while coordinating with all stakeholders throughout the development and operational phases.
Together with Vinpearl’s world-class hospitality brand, the addition of four premium IHG hotels will help realize a 7,000-room accommodation ecosystem at Vinhomes Green Paradise Can Gio, meeting the growing demand for extended stays and diverse experiences year-round in Can Gio and Ho Chi Minh City.
Complementing the hospitality offering, a series of large-scale entertainment and resort facilities unique to Vinhomes Green Paradise Can Gio will further elevate the destination. These include the 122-hectare VinWonders theme park featuring the world’s tallest artificial snow mountain and nearly 200 attractions, the 5,000-seat Blue Waves Theater, the 800-hectare Paradise Lagoon, the five-star international cruise port Landmark Harbour, and two 18-hole international-standard golf courses. Together, these developments aim to position Can Gio as a globally-recognized tourism and resort hub, targeting 40 million visitors annually and standing alongside leading destinations in Vietnam and worldwide.
Mr. Rajit Sukumaran, Senior Vice President and Managing Director, East Asia & Pacific, IHG Hotels & Resorts, said: “This agreement marks the beginning of a strategic partnership between IHG and Vingroup. Bringing four of our standout brands to Vinhomes Green Paradise Can Gio reflects the diversity of our portfolio, as well as our strong commitment to supporting Vietnam’s goal of becoming a leading global tourism destination. With brands spanning multiple segments, we believe this collaboration will help create an integrated hospitality ecosystem that meets the diverse needs of travelers at one of Vietnam’s most significant developments.”
Ms. Ngo Thi Huong, Chief Executive Officer of Vinpearl Joint Stock Company, said: “We selected IHG not only for its global brand portfolio but also for its proven operational expertise across international markets. Introducing InterContinental, Crowne Plaza, Holiday Inn Express, and Garner to Vinhomes Green Paradise Can Gio is a key step in completing our service structure and establishing international operating standards for the mega project’s hotel system. With this partnership as a foundation, we believe Vinhomes Green Paradise will progressively emerge as a world-class destination, where a fully integrated ecosystem continues to enhance its appeal to residents and both domestic and international visitors.”
Vinhomes Green Paradise is located in the southeastern part of Ho Chi Minh City. Construction began on April 19, 2025, with a total area of 2,870 hectares. The development features three sides facing the sea and is adjacent to the Can Gio Mangrove Biosphere Reserve, a UNESCO-recognized site. The project is being developed to leading ESG++ standards, integrating green, smart, ecological, and regenerative principles.
The development benefits from a well-connected transport infrastructure network, including the Ben Thanh – Can Gio high-speed railway, which will reduce travel time from central Ho Chi Minh City to just 13 minutes, the Can Gio Bridge, the interchange connecting Rung Sac Road with the Ben Luc – Long Thanh Expressway, and the Can Gio – Vung Tau sea-crossing route, enabling travel between two major tourism hubs in just 10 minutes.
With a diverse range of accommodation options, internationally-standardized hotel systems, and a wide array of cultural, artistic, sports, and entertainment facilities aligned with green, smart, and community-friendly principles, Vinhomes Green Paradise Can Gio stands out as a rare mega urban development that both sets new benchmarks for ESG living and delivers a world-class tourism and resort experience.
Hashtag: #Vinhomes
The issuer is solely responsible for the content of this announcement.
About IHG Hotels & Resorts:
IHG Hotels & Resorts is a global hospitality company with a portfolio of 21 brands and IHG One Rewards, one of the world’s largest hotel loyalty programs with over 160 million members. IHG currently franchises, leases, manages, or owns more than 6,900 hotels across over 100 countries, with more than 2,300 hotels in its development pipeline.
IHG’s brand portfolio spans Luxury & Lifestyle, Premium, Essentials, and Suites segments, including well-known brands such as Six Senses, Regent, InterContinental, Crowne Plaza, Holiday Inn Express, Garner, Staybridge Suites, and Candlewood Suites.
About Vinhomes
Vinhomes is Vietnam’s leading real estate developer, pioneering the development of large-scale, well-planned urban areas with integrated amenities, green living environments, and modern lifestyles. In addition to 36 urban developments currently in operation nationwide, Vinhomes continues to focus on building next-generation mega and super urban developments of regional scale and significance, aspiring to create some of the most livable cities in the world while significantly transforming Vietnam’s urban landscape.
For more information, please visit https://vinhomes.vn/vi
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn